<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803203</url>
  </required_header>
  <id_info>
    <org_study_id>16-033</org_study_id>
    <nct_id>NCT02803203</nct_id>
  </id_info>
  <brief_title>Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers</brief_title>
  <official_title>A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of combining the drugs osimertinib and
      bevacizumab at different dose levels. The investigators want to find out what effects, good
      and/or bad, taking osimertinib and bevacizumab has on the patient and lung cancer. This study
      will try to find the best dose of osimertinib and bevacizumab given together that does not
      cause significant side effects. Once the investigators determine that combining osimertinib
      and bevacizumab is safe, they want to see if the combination is effective in treating lung
      cancers with the EGFR mutation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD) (Phase I)</measure>
    <time_frame>1 year</time_frame>
    <description>The MTD (maximum tolerated dose)/recommended phase 2 dose will be the highest dose level at which &lt;1 DLT is detected in the first cycle for 6 treated patients. If only 3 patients are treated at a dose level being considered for the MTD, an additional 3 patients will be enrolled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression-free survival (Phase II)</measure>
    <time_frame>12 months</time_frame>
    <description>Tumor response will be assessed using RECIST 1.1. A CT chest/abdomen/pelvis will be performed to demonstrate all known areas of measurable disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>EGFR-mutant Lung Cancers</condition>
  <arm_group>
    <arm_group_label>osimertinib and bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1:
3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks
Phase 2:
Use MTD determined during phase 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>osimertinib</intervention_name>
    <arm_group_label>osimertinib and bevacizumab</arm_group_label>
    <other_name>AZD9291</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>osimertinib and bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Advanced biopsy-proven metastatic non-small cell lung cancer

          -  Somatic activating mutation in EGFR

          -  No prior treatment with an EGFR TKI

          -  No prior treatment with a VEGF inhibitor

          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated

          -  Karnofsky performance status (KPS) ≥ 70%

          -  Age &gt;18 years old

          -  Adequate organ function

               -  AST, ALT ≤ 3 x ULN

               -  Total bilirubin ≤ 1.5x ULN

               -  Creatinine ≤ 1.5x ULN OR calculated creatinine clearance &gt; 60ml/min

               -  Absolute neutrophil count (ANC) ≥ 1000 cells/mm3

               -  Hemoglobin≥8.0 g/dL

               -  Platelets ≥100,000/mm3

        Exclusion Criteria:

          -  Any contra-indications to bevacizumab which include but are not limited to recent

               1. Any previous venous thromboembolism &gt; NCI CTCAE Grade 3

               2. Severe uncontrolled hypertension (systolic blood pressure ≥150 mmHg and/or
                  diastolic blood pressure ≥ 100mmHg)

               3. Cardiovascular disease including stroke of myocardial infarction &lt;6 months prior
                  to study enrollment, New York Heart Association Grade 2 or greater congestive
                  heart failure, serious cardiac arrythmia uncontrolled by medication

               4. Hemorrhagic brain metastases. Asymptomatic (not requiring escalating doses of
                  steroids) brain metastases are acceptable.

               5. History of severe proteinuria (urine dipstick ≥ 2+ or 24 hr urine &gt; 2gm/24hr)

               6. Prior history of hypertensive crisis or hypertensive encephalopathy

               7. History of a central nervous system disease (e.g. seizures) unrelated to cancer
                  unless adequately treated with standard medical therapy

               8. Significant vascular disease (e.g. aortic aneurysm requiring surgical repair)≥ 6
                  months prior to study enrollment

               9. History of hemoptysis (≥1/2 teaspoon of bright red blood per episode) within the
                  last 3 months

              10. Evidence of a bleeding diathesis or significant coagulopathy (in the absence of
                  therapeutic anticoagulation)

              11. Current or recent (within 10 days of study drug start) use of aspirin (&gt;325mg
                  daily), clopidogrel (&gt;75mg daily).

              12. Recent initiation of full dose oral or parental anticoagulants that have not been
                  in place for at least 2 weeks.

              13. Tumor invading or abutting major blood vessels

              14. Tumor histology classified by squamous cell histology.

              15. Any history of abdominal fistula or GI perforation within 6 months of study
                  enrollment

          -  Pregnant or lactating women

          -  Any type of systemic anticancer therapy (chemotherapy or experimental drugs) within 2
             weeks of starting treatment on protocol

          -  Any radiotherapy within 1 week of starting treatment on protocol

          -  Any major surgery within 4 weeks of starting treatment on protocol

          -  Any evidence of clinically significant interstitial lung disease

          -  Known hypersensitivity to any component of bevacizumab and osimertinib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Yu, MD</last_name>
    <phone>646 888 4274.</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Kris, MD</last_name>
    <phone>646-888-4205</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
    <investigator>
      <last_name>Helena Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
    <investigator>
      <last_name>Helena Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
    <contact_backup>
      <last_name>Mark Kris, MD</last_name>
      <phone>646-888-4205</phone>
    </contact_backup>
    <investigator>
      <last_name>Helena Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osimertinib</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>metastatic</keyword>
  <keyword>16-033</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

